Posted in | News | Business

BASF to Establish Production Base for Water Treatment and Paper Chemicals in China

BASF has decided to establish a wholly-owned world-scale production base for water treatment and paper chemicals in Nanjing, China, with the construction of a 40,000 t/a quaternized cationic monomers plant and a 20,000 t/a cationic polyacrylamides plant.

The two BASF plants, which are designed to high international standards of safety and energy efficiency, are expected to start up production in the third quarter of 2012. They mark the first Asian manufacturing of these products for BASF.

"This investment underlines our long-term commitment to China both in economic and environmental terms," said Dr. Albert Heuser, President Market and Business Development Asia Pacific. "The establishment of these plants is part of our growth strategy for Asia Pacific to double our sales by 2020 while contributing to a sustainable future."

Cationic monomers are a key feedstock for cationic polyacrylamides. Cationic polyacrylamides are used as organic flocculants in the water treatment industry and as retention aids in the paper industry.

The water treatment and papermaking industries are growing at a high rate in Asia, particularly in China. This is a result of substantial investment in water treatment infrastructure and strongly increasing paper consumption, fuelled by high growth in regional GDP.

"We are one of the leading suppliers to the water treatment industry with a strong platform for future growth in a very attractive market. This investment is our long-term response to the growing demand from our customers in Asia," said Hans W. Reiners, President Performance Chemicals division, which also includes BASF's Water Solutions business. "Nanjing is an ideal location for such an investment as it offers BASF a high degree of backward integration", Reiners added.

" Following our recent announcement of plans to build a plant for XSB dispersions in Huizhou, South China, this investment further demonstrates our commitment to the fast-growing paper industry in emerging Asia, especially in China. Our ability to produce within the region will underpin our supply reliability and the success of our customers," said EngSoo Chew, Senior Vice President Paper Chemicals Asia Pacific.

The plants will be built according to BASF's high global standards of safety and environmental protection. This process for planning a plant is laid down in a binding guideline that is valid throughout the BASF Group. The five-step review system for environmental protection, health and safety (EHS reviews) covers all aspects of process safety, occupational health and environmental protection. Furthermore, BASF places particular importance on training its safety experts worldwide to implement the same high safety standards in all its production facilities.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BASF Corporation. (2019, February 10). BASF to Establish Production Base for Water Treatment and Paper Chemicals in China. AZoM. Retrieved on November 21, 2024 from https://www.azom.com/news.aspx?newsID=24601.

  • MLA

    BASF Corporation. "BASF to Establish Production Base for Water Treatment and Paper Chemicals in China". AZoM. 21 November 2024. <https://www.azom.com/news.aspx?newsID=24601>.

  • Chicago

    BASF Corporation. "BASF to Establish Production Base for Water Treatment and Paper Chemicals in China". AZoM. https://www.azom.com/news.aspx?newsID=24601. (accessed November 21, 2024).

  • Harvard

    BASF Corporation. 2019. BASF to Establish Production Base for Water Treatment and Paper Chemicals in China. AZoM, viewed 21 November 2024, https://www.azom.com/news.aspx?newsID=24601.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.